These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 14651226

  • 1. Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocytic leukemia.
    Osman I, Akin U, Ismet A, Meral B, Hamdi A, Haluk K.
    Haematologia (Budap); 1996; 27(2):93-7. PubMed ID: 14651226
    [Abstract] [Full Text] [Related]

  • 2. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K.
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase II study of mitoxantrone and cytarabine in acute myeloid leukemia.
    Brito-Babapulle F, Catovsky D, Slocombe G, Newland AC, Marcus RE, Goldman JM, Galton DA.
    Cancer Treat Rep; 1987 Feb; 71(2):161-3. PubMed ID: 3467843
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC, Lin SF, Yao M, Chen TY, Tsao CJ, Chen TP.
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia.
    Koc Y, Oyan B, Kars A, Tekuzman G, Canpinar H, Kansu E.
    Hematol Oncol; 2004 Jun; 22(2):43-53. PubMed ID: 15386563
    [Abstract] [Full Text] [Related]

  • 8. Idarubicin combined with intermediate-dose cytosine arabinoside in the treatment of refractory acute leukemia.
    Leone G, Pagano L, Marra R, Di Pietro N, Storti S, Sica S, D'Onofrio G, Ganzina F.
    Haematologica; 1989 Jun; 74(1):57-61. PubMed ID: 2498185
    [Abstract] [Full Text] [Related]

  • 9. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T, Takahashi M, Ogawa Y, Honda S, Ohno R, Japan Adult Leukemia Study Group AML 97 Study.
    Cancer; 2005 Dec 15; 104(12):2726-34. PubMed ID: 16284985
    [Abstract] [Full Text] [Related]

  • 10. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T, Ogawa M, Yamada K, Kimura K, Ohhashi Y.
    Gan To Kagaku Ryoho; 1993 Oct 15; 20(13):1995-2005. PubMed ID: 8215474
    [Abstract] [Full Text] [Related]

  • 11. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
    Urabe A, Mizoguchi H, Hoshino S, Nomura T, Dan K, Toyama K, Kimura M, Ogawa T, Yamaguchi H, Mutoh Y.
    Int J Hematol; 1991 Feb 15; 54(1):75-7. PubMed ID: 1954354
    [Abstract] [Full Text] [Related]

  • 12. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, Kim HJ, Kim HS, Song HS, Park JW, Ahn HS, Chung TJ, Cho KS, Lee KS, Choi YM.
    Semin Hematol; 1996 Oct 15; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [Abstract] [Full Text] [Related]

  • 13. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
    Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, Holland JF.
    Leukemia; 1987 Jul 15; 1(7):565-7. PubMed ID: 3478540
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Hiddemann W, Büchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzenburg S, Donhuijsen-Ant R.
    Leukemia; 1990 Sep 15; 4(9):637-40. PubMed ID: 2395383
    [Abstract] [Full Text] [Related]

  • 20. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
    Takemoto Y, Sampi K, Kuraishi Y, Okabe K, Tamura K, Mizoguchi H, Saito H, Masaoka T, Ogawa M.
    Int J Hematol; 1999 Jul 15; 70(1):20-5. PubMed ID: 10446490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.